Maria Sampalis
Optometrist · Warwick, RINPI 1740470566
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 44.8% of the total. Reporting peaked in 2021 at $65,769 and has fallen 79.8% since, to $13,261 in 2025. Among optometrist clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 437 payments — averaging $308.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$60K
- Alcon$21K
- AbbVie$11K
- Topcon Healthcare, Inc.$10K
- Coopervision Inc.$7K
- Reichert, Inc.$5K
- plus $21K from 25 others
What the payments were for
- Consulting fees$32,62324%
- Speaking & faculty fees$77,41058%
- Grants$6,0004%
- Travel & lodging$3,3182%
- Food & beverage$15,10411%
- Gifts$370%
- Entertainment$1250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 10 | $60,307 |
| Alcon | 102 | $20,940 |
| AbbVie(2 entities) | 42 | $11,094 |
| Topcon Healthcare, Inc. | 7 | $9,666 |
| Coopervision Inc. | 41 | $6,990 |
| Reichert, Inc. | 1 | $4,680 |
| Harrow Eye, LLC | 13 | $4,394 |
| Tarsus Pharmaceuticals, Inc. | 33 | $3,918 |
| Bausch & Lomb Americas Inc. | 60 | $3,821 |
| Maculogix, Inc. | 3 | $3,382 |
| Sun Pharmaceutical Industries Inc. | 41 | $1,313 |
| Carl Zeiss Meditec, Inc. | 3 | $937 |
| Oyster Point Pharma, Inc. | 22 | $538 |
| Glaukos Corporation | 9 | $520 |
| Sparca Ltd | 1 | $500 |
| Dompe US, Inc. | 9 | $308 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $225 |
| Thea Pharma Inc. | 4 | $221 |
| ABB Con-cise Optical Group LLC | 8 | $203 |
| Lumenis BE Inc | 1 | $154 |
| Optos, Inc. | 2 | $125 |
| Heru, Inc. | 1 | $122 |
| Shire North American Group Inc | 1 | $66 |
| Lombart Brothers, Inc. | 2 | $29 |
| Quidel Corporation | 2 | $26 |
| Tearlab Corp | 1 | $26 |
| Oasis Medical, Inc. | 1 | $26 |
| LKC Technologies, Inc. | 1 | $25 |
| Sight Sciences, Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$60,101
- VUITY$6,939
- Precision 7$6,741
- TONO-VERA TONOMETER US STARTER KIT HUMAN RECHARGABLE$4,680
- VEVYE$3,990
- AdaptDx$3,350
- DAILIES TOTAL1$2,317
- Non-Product Brand Specific$2,250
- MyDay Contact Lens$2,229
- XIIDRA$1,660
- MIEBO$1,660
- DAILIES TOTAL1 Multifocal$1,400
- Precision 1$1,148
- INFUSE$1,127
- RESTASIS$1,122
- CIRRUS HD-OCT$920
- CLARUS$920
- XDEMVY$900
- Multiple Brands Contact Lens$750
- CEQUA$501
How this compares
$134,616 in reported general payments places this provider in the 95th percentile of 226 optometrist providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 21 | $12,003 |
| MieboPerfluorohexyloctane/Pf | 12 | $9,873 |
| LumiganBimatoprost | 11 | $2,670 |
| Latanoprost | 154 | $1,539 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 14 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $11,094 | $14,67332 claims |
| Bausch & Lomb Americas Inc.Miebo | $3,821 | $9,87312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 optometrist providers in Rhode Island.
Other optometrist in Warwick
- Stephen MontaquilaWarwick$51K
- Matthew DoyleWarwick$9K
- Georgia PatsiopoulosWarwick$9K
- Alyssa CampagnoneWarwick$5K
- Earle ScharffWarwick$4K
- Lam DaoWarwick$3K
- Kristin BrennanWarwick$3K
- Michele PalazzoloWarwick$2K
- Iris MillerWarwick$2K
- Tiffany GrahamWarwick$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.